Caffeine Disposition After Inhalation

Pharmacokinetics and Pharmacodynamics of a 100 mg Caffeine Dose After Oral Consumption of an Energy Drink or Inhalation Using the Aeroshot Administration Device

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02184104

Enrollment

Registered

2014-07-09

Start date

2014-07-31

Completion date

2017-03-20

Last updated

2017-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

caffeine, pharmacokinetics, pharmacodynamics

Brief summary

The purpose of this study is to determine how fast caffeine gets into your body with a product called Aeroshot™. Aeroshot™ is a lipstick sized device that you slide open and then put your mouth over the opening and inhale. A fine powder containing 100 mg of caffeine is deposited on your tongue and the inside of your mouth. Caffeine will be absorbed through the membranes in your mouth or swallowed and then absorbed in your stomach. We will compare the absorption of caffeine after using the Aeroshot™ with the absorption after drinking an energy drink by taking 15 blood samples over 8 hours and measuring the caffeine levels in your blood. You will also be asked to fill out some scales to measure the effects you feel after the caffeine dose. We hypothesize that caffeine absorption after inhalation will be faster than after an energy drink.

Interventions

DIETARY_SUPPLEMENTCaffeine

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy volunteer * non-smoker

Exclusion criteria

* Take chronic medication * Co-existing diseases * Platelet count less than 100,000/uL (per microliter) * Acute or chronic psychiatric condition * Consume more than 300 mg of caffeine per day * Participated in another study within last 30 days or donated blood in last 6 weeks

Design outcomes

Primary

Measure	Time frame	Description
Caffeine plasma concentration	0, 1, 2, 5, 10, 15, 20, 30, 40, 60 minutes and 2, 3, 4, 6, 8 hours	These are the collection times of blood samples relative to when the caffeine dose was consumed.

Secondary

Measure	Time frame	Description
Caffeine effects	0, 1, 2, 5, 10, 15, 20, 30, 40, 60 minutes, and 2, 3, 4, 6, 8 hours	Subjects will complete seven analog scales to assess the effects that they feel after the caffeine dose.

Other

Measure	Time frame	Description
Cardiovascular effects	0, 1, 2, 5, 10, 15, 20, 30, 40, 60 minutes, and 2, 3, 4, 6, 8 hours	The heart rate and blood pressure will be recorded at the time of each blood collection.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026